Analysis of the cyclin D1/p16/pRb pathway in parathyroid adenomas

被引:6
作者
Cristóbal, E
Arribas, B
Tardío, J
Alcázar, JA
Martínez-Montero, JC
Carrión, R
Polo, JR
Gil, L
Azañedo, M
Rojas, JM
Menárguez, J
机构
[1] Univ Madrid, Hosp Gen Gregorio Maranon, Dept Pathol, Madrid 28007, Spain
[2] Univ Madrid, Hosp Gen Gregorio Maranon, Dept Surg, Madrid 28007, Spain
[3] Univ Madrid, Hosp Gen Gregorio Maranon, Dept Oncol, Madrid 28007, Spain
[4] Hosp El Escorial, Dept Pathol, Madrid, Spain
[5] Inst Oftalm, Dept Pathol, Madrid, Spain
[6] Ctr Nacl Biol Fundamental, Unidad Biol Celular, Inst Salud Carlos III, Madrid, Spain
关键词
parathyroid adenoma; parathyroid glands; cyclin D1; p16; pRb; Ki-67; cell cycle;
D O I
10.1385/EP:11:3:259
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cyclin D1/p16/pRb pathway controlling G1 --> S cell cycle checkpoint is frequently altered in human tumors. Currently, scarce data are available for parathyroid tumors. We have studied 46 parathyroid adenomas (PTAs) and 12 normal parathyroid glands (PTGs) by immunohistochemistry with cyclin DI (CD1), p16, pRb, and Ki-67 antibodies. We observed CD1 expression in 89%, p16 in 70%, and pRb in 100% of PTAs. Statistically significant differences with normal PTGs were found only concerning p16 expression (p < 0.05). Proliferating rate (Ki-67) was always low, although significantly higher than in normal PTGs. Our findings demonstrate the presence of alterations in the CD1/p16/pRb pathway in PTAs, consisting in p16 overexpression apparently unrelated to pRb downregulation. On the other hand, we did not find significant differences in CD1 expression between PTAs and normal PTGs, suggesting CD1 overexpression could be a physiological event in parathyroid tissue.
引用
收藏
页码:259 / 266
页数:8
相关论文
共 49 条
[11]   Evaluation of retinoblastoma and Ki-67 immunostaining as diagnostic markers of benign and malignant parathyroid disease [J].
Farnebo, F ;
Auer, G ;
Farnebo, LO ;
Teh, BT ;
Twigg, S ;
Aspenblad, U ;
Thompson, NW ;
Grimelius, L ;
Larsson, C ;
Sandelin, K .
WORLD JOURNAL OF SURGERY, 1999, 23 (01) :68-74
[12]   GENETIC ABNORMALITIES IN SPORADIC PARATHYROID ADENOMAS [J].
FRIEDMAN, E ;
BALE, AE ;
MARX, SJ ;
NORTON, JA ;
ARNOLD, A ;
TU, T ;
AURBACH, GD ;
SPIEGEL, AM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 71 (02) :293-297
[13]  
Geradts J, 1996, MODERN PATHOL, V9, P339
[14]  
GERADTS J, 1995, CANCER RES, V55, P6006
[15]   Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas [J].
Gorgoulis, VG ;
Koutroumbi, EN ;
Kotsinas, A ;
Zacharatos, P ;
Markopoulos, C ;
Giannikos, L ;
Kyriakou, V ;
Voulgaris, Z ;
Gogas, I ;
Kittas, C .
MOLECULAR MEDICINE, 1998, 4 (12) :807-822
[16]   Somatic mutation of the MEN1 gene in parathyroid tumours [J].
Heppner, C ;
Kester, MB ;
Agarwal, SK ;
Debelenko, LV ;
EmmertBuck, MR ;
Guru, SC ;
Manickam, P ;
Olufemi, SE ;
Skarulis, MC ;
Doppman, JL ;
Alexander, RH ;
Kim, YS ;
Saggar, SK ;
Lubensky, IA ;
Zhuang, ZP ;
Liotta, LA ;
Chandrasekharappa, SC ;
Collins, FS ;
Spiegel, AM ;
Burns, AL ;
Marx, SJ .
NATURE GENETICS, 1997, 16 (04) :375-378
[17]  
Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO
[18]  
2-5
[19]   Cyclin D1/PRAD1 expression in parathyroid adenomas: An immunohistochemical study [J].
Hsi, ED ;
Zukerberg, LR ;
Yang, WI ;
Arnold, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (05) :1736-1739
[20]  
JARES P, 1994, CANCER RES, V54, P4813